$BDSX
Biodesix Inc

2023 Q1 Form 10-K Financial Statement

#000095017023006092 Filed on March 06, 2023

View on sec.gov

Income Statement

Concept 2023 Q1 2022 Q4 2022
Revenue $9.056M $9.607M $38.21M
YoY Change 38.3% 32.99% -29.89%
Cost Of Revenue $3.169M $3.306M $14.15M
YoY Change -2.04% 32.61% -53.62%
Gross Profit $5.887M $6.301M $24.06M
YoY Change 77.69% 33.19% 0.29%
Gross Profit Margin 65.01% 65.59% 62.96%
Selling, General & Admin $18.99M $16.63M $61.46M
YoY Change 31.08% 22.63% 21.67%
% of Gross Profit 322.56% 263.86% 255.47%
Research & Development $3.251M $3.565M $13.10M
YoY Change 1.4% 25.0% 2.45%
% of Gross Profit 55.22% 56.58% 54.46%
Depreciation & Amortization $300.0K $898.0K $3.597M
YoY Change -25.0% 5.03% 13.18%
% of Gross Profit 5.1% 14.25% 14.95%
Operating Expenses $25.43M $20.19M $88.80M
YoY Change 21.04% 23.04% -6.96%
Operating Profit -$16.37M -$13.89M -$50.59M
YoY Change 13.22% 18.93% 23.56%
Interest Expense $2.391M -$2.550M $8.072M
YoY Change 110.29% 70.45% 79.06%
% of Operating Profit
Other Income/Expense, Net -$2.329M $79.00K -$14.86M
YoY Change 107.02% -890.0% 569.67%
Pretax Income -$18.70M -$20.34M -$65.45M
YoY Change 19.99% 53.12% 51.64%
Income Tax $0.00 $0.00
% Of Pretax Income
Net Earnings -$18.70M -$20.34M -$65.45M
YoY Change 19.99% 53.12% 51.64%
Net Earnings / Revenue -206.52% -211.7% -171.27%
Basic Earnings Per Share -$0.24 -$1.55
Diluted Earnings Per Share -$0.24 -$0.35 -$1.55
COMMON SHARES
Basic Shares Outstanding 77.97M 42.09M 42.10M
Diluted Shares Outstanding 77.77M 42.10M

Balance Sheet

Concept 2023 Q1 2022 Q4 2022
SHORT-TERM ASSETS
Cash & Short-Term Investments $25.28M $43.09M $43.09M
YoY Change 53.86% 31.72% 31.72%
Cash & Equivalents $25.28M $43.09M $43.09M
Short-Term Investments
Other Short-Term Assets $4.608M $5.181M $5.181M
YoY Change -34.47% -28.49% -28.49%
Inventory
Prepaid Expenses
Receivables $4.901M $5.065M $5.065M
Other Receivables $0.00 $0.00 $0.00
Total Short-Term Assets $34.78M $53.33M $53.33M
YoY Change 27.73% 22.29% 22.29%
LONG-TERM ASSETS
Property, Plant & Equipment $13.10M $5.848M $8.821M
YoY Change 225.15% 39.94% 111.08%
Goodwill $15.03M $15.03M
YoY Change 0.0% 0.0%
Intangibles $9.311M $9.797M
YoY Change -16.35% -15.67%
Long-Term Investments
YoY Change
Other Assets $6.376M $5.923M $5.923M
YoY Change 217.37% 257.45% 257.45%
Total Long-Term Assets $46.01M $39.57M $39.57M
YoY Change 33.68% 21.82% 21.82%
TOTAL ASSETS
Total Short-Term Assets $34.78M $53.33M $53.33M
Total Long-Term Assets $46.01M $39.57M $39.57M
Total Assets $80.79M $92.91M $92.91M
YoY Change 31.05% 22.09% 22.09%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $1.563M $1.685M $1.685M
YoY Change -26.27% 1.38% 1.38%
Accrued Expenses $5.740M $8.218M $7.446M
YoY Change -7.01% 7.21% 51.99%
Deferred Revenue $1.100M $1.000M
YoY Change -56.0% -47.37%
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due $50.00K $49.00K $49.00K
YoY Change -1.96% 157.89% 157.89%
Total Short-Term Liabilities $22.10M $22.84M $22.84M
YoY Change -25.87% -21.14% -21.14%
LONG-TERM LIABILITIES
Long-Term Debt $25.08M $25.00M $25.00M
YoY Change 149.47% 150.22% 150.22%
Other Long-Term Liabilities $648.0K $558.0K $24.46M
YoY Change 5.37% -59.83% 40.42%
Total Long-Term Liabilities $54.15M $49.46M $49.46M
YoY Change 125.05% 80.45% 80.45%
TOTAL LIABILITIES
Total Short-Term Liabilities $22.10M $22.84M $22.84M
Total Long-Term Liabilities $54.15M $49.46M $49.46M
Total Liabilities $76.24M $72.30M $72.30M
YoY Change 41.53% 28.26% 28.26%
SHAREHOLDERS EQUITY
Retained Earnings -$386.1M -$367.4M
YoY Change 21.59% 21.67%
Common Stock $78.00K $78.00K
YoY Change 143.75% 151.61%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $4.550M $20.61M $20.61M
YoY Change
Total Liabilities & Shareholders Equity $80.79M $92.91M $92.91M
YoY Change 31.05% 22.09% 22.09%

Cashflow Statement

Concept 2023 Q1 2022 Q4 2022
OPERATING ACTIVITIES
Net Income -$18.70M -$20.34M -$65.45M
YoY Change 19.99% 53.12% 51.64%
Depreciation, Depletion And Amortization $300.0K $898.0K $3.597M
YoY Change -25.0% 5.03% 13.18%
Cash From Operating Activities -$7.686M -$11.95M -$44.97M
YoY Change -41.32% 17.17% 59.35%
INVESTING ACTIVITIES
Capital Expenditures $7.676M $1.987M $3.298M
YoY Change 2829.77% -409.98% 47.17%
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities -$7.706M -$1.987M -$3.534M
YoY Change 2089.2% 209.98% 38.75%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net $59.54M
YoY Change 264.3%
Debt Paid & Issued, Net $12.00K $23.90M $28.60M
YoY Change 9.09% -37.03%
Cash From Financing Activities -2.421M 41.85M 58.88M
YoY Change -14.57% -1059.16% 4565.77%
NET CHANGE
Cash From Operating Activities -7.686M -11.95M -44.97M
Cash From Investing Activities -7.706M -1.987M -3.534M
Cash From Financing Activities -2.421M 41.85M 58.88M
Net Change In Cash -17.81M 27.91M 10.38M
YoY Change 9.38% -283.63% -135.16%
FREE CASH FLOW
Cash From Operating Activities -$7.686M -$11.95M -$44.97M
Capital Expenditures $7.676M $1.987M $3.298M
Free Cash Flow -$15.36M -$13.94M -$48.27M
YoY Change 14.98% 45.82% 58.45%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2022 us-gaap Number Of Operating Segments
NumberOfOperatingSegments
1
CY2021Q4 us-gaap Restricted Cash Current Asset Statement Of Financial Position Extensible List
RestrictedCashCurrentAssetStatementOfFinancialPositionExtensibleList
http://fasb.org/us-gaap/2022#OtherAssetsCurrent
CY2022 bdsx Lease Expiration Month Year
LeaseExpirationMonthYear
2023-01
CY2022Q4 us-gaap Restricted Cash Current Asset Statement Of Financial Position Extensible List
RestrictedCashCurrentAssetStatementOfFinancialPositionExtensibleList
http://fasb.org/us-gaap/2022#OtherAssetsCurrent
CY2022 dei Entity Central Index Key
EntityCentralIndexKey
0001439725
CY2022 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2022 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
FY
CY2021Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2022Q1 us-gaap Operating Lease Right Of Use Asset Statement Of Financial Position Extensible List
OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList
http://fasb.org/us-gaap/2022#OperatingLeaseRightOfUseAsset
CY2022 dei Amendment Flag
AmendmentFlag
false
CY2022Q4 us-gaap Preferred Stock Value
PreferredStockValue
CY2021Q4 us-gaap Preferred Stock Value
PreferredStockValue
CY2022Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2022Q1 us-gaap Operating Lease Liability Statement Of Financial Position Extensible List
OperatingLeaseLiabilityStatementOfFinancialPositionExtensibleList
http://fasb.org/us-gaap/2022#OperatingLeaseLiability
CY2022 dei Document Type
DocumentType
10-K
CY2022 dei Document Annual Report
DocumentAnnualReport
true
CY2022 dei Document Period End Date
DocumentPeriodEndDate
2022-12-31
CY2022 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2022
CY2022 dei Document Transition Report
DocumentTransitionReport
false
CY2022 dei Entity File Number
EntityFileNumber
001-39659
CY2022 dei Entity Registrant Name
EntityRegistrantName
Biodesix, Inc.
CY2022 dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
CY2022 dei Entity Tax Identification Number
EntityTaxIdentificationNumber
20-3986492
CY2022 dei Entity Address Address Line1
EntityAddressAddressLine1
2970 Wilderness Place
CY2022 dei Entity Address Address Line2
EntityAddressAddressLine2
Suite 100
CY2022 dei Entity Address City Or Town
EntityAddressCityOrTown
Boulder
CY2022 dei Entity Address State Or Province
EntityAddressStateOrProvince
CO
CY2022 dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
80301
CY2022 dei City Area Code
CityAreaCode
303
CY2022 dei Local Phone Number
LocalPhoneNumber
417-0500
CY2022 dei Security12b Title
Security12bTitle
Common Stock, par value $0.001 per share
CY2022 dei Trading Symbol
TradingSymbol
BDSX
CY2022 dei Icfr Auditor Attestation Flag
IcfrAuditorAttestationFlag
false
CY2022 dei Entity Shell Company
EntityShellCompany
false
CY2022 dei Security Exchange Name
SecurityExchangeName
NASDAQ
CY2022 dei Entity Well Known Seasoned Issuer
EntityWellKnownSeasonedIssuer
No
CY2022 dei Entity Voluntary Filers
EntityVoluntaryFilers
Yes
CY2022 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2022 dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
CY2022 dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
CY2022 dei Entity Small Business
EntitySmallBusiness
true
CY2022Q2 dei Entity Public Float
EntityPublicFloat
34100000
CY2023Q1 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
77974861
CY2022 dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
true
CY2022 dei Entity Ex Transition Period
EntityExTransitionPeriod
false
CY2022 dei Auditor Name
AuditorName
KPMG LLP
CY2022 dei Auditor Location
AuditorLocation
Denver, CO
CY2022 dei Auditor Firm
AuditorFirmId
185
CY2022Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
43088000
CY2021Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
32712000
CY2022Q4 us-gaap Allowance For Doubtful Accounts Receivable
AllowanceForDoubtfulAccountsReceivable
118000
CY2021Q4 us-gaap Allowance For Doubtful Accounts Receivable
AllowanceForDoubtfulAccountsReceivable
158000
CY2022Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
5065000
CY2021Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
3656000
CY2022Q4 us-gaap Other Assets Current
OtherAssetsCurrent
5181000
CY2021Q4 us-gaap Other Assets Current
OtherAssetsCurrent
7245000
CY2022Q4 us-gaap Assets Current
AssetsCurrent
53334000
CY2021Q4 us-gaap Assets Current
AssetsCurrent
43613000
CY2022Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
5848000
CY2021Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
4179000
CY2022Q4 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
9797000
CY2021Q4 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
11617000
CY2022Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
2973000
CY2022Q4 us-gaap Goodwill
Goodwill
15031000
CY2021Q4 us-gaap Goodwill
Goodwill
15031000
CY2022Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
5923000
CY2021Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
1657000
CY2022Q4 us-gaap Assets Noncurrent
AssetsNoncurrent
39572000
CY2021Q4 us-gaap Assets Noncurrent
AssetsNoncurrent
32484000
CY2022Q4 us-gaap Assets
Assets
92906000
CY2021Q4 us-gaap Assets
Assets
76097000
CY2022Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
1685000
CY2021Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
1662000
CY2022Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
8218000
CY2021Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
7665000
CY2022Q4 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
962000
CY2021Q4 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
1850000
CY2022Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
1543000
CY2022Q4 us-gaap Business Combination Contingent Consideration Liability Current
BusinessCombinationContingentConsiderationLiabilityCurrent
10341000
CY2021Q4 us-gaap Business Combination Contingent Consideration Liability Current
BusinessCombinationContingentConsiderationLiabilityCurrent
17764000
CY2022Q4 us-gaap Notes Payable To Bank Current
NotesPayableToBankCurrent
49000
CY2021Q4 us-gaap Notes Payable To Bank Current
NotesPayableToBankCurrent
19000
CY2022Q4 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
41000
CY2022Q4 us-gaap Liabilities Current
LiabilitiesCurrent
22839000
CY2021Q4 us-gaap Liabilities Current
LiabilitiesCurrent
28960000
CY2022Q4 us-gaap Business Combination Contingent Consideration Liability Noncurrent
BusinessCombinationContingentConsiderationLiabilityNoncurrent
18645000
CY2021Q4 us-gaap Business Combination Contingent Consideration Liability Noncurrent
BusinessCombinationContingentConsiderationLiabilityNoncurrent
16028000
CY2022Q4 us-gaap Long Term Notes Payable
LongTermNotesPayable
25004000
CY2021Q4 us-gaap Long Term Notes Payable
LongTermNotesPayable
9993000
CY2022Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
558000
CY2022Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
5254000
CY2021Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
1389000
CY2022Q4 us-gaap Liabilities Noncurrent
LiabilitiesNoncurrent
49461000
CY2021Q4 us-gaap Liabilities Noncurrent
LiabilitiesNoncurrent
27410000
CY2022Q4 us-gaap Liabilities
Liabilities
72300000
CY2021Q4 us-gaap Liabilities
Liabilities
56370000
CY2021Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2022Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2021Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000
CY2022Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000
CY2021Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2022Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2022Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2021Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2021Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2022Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2021Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
200000000
CY2022Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
200000000
CY2022Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
77614358
CY2022Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
77614358
CY2021Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
30789649
CY2021Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
30789649
CY2022Q4 us-gaap Common Stock Value
CommonStockValue
78000
CY2021Q4 us-gaap Common Stock Value
CommonStockValue
31000
CY2022Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
387948000
CY2021Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
321669000
CY2022Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-367420000
CY2021Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-301973000
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
20606000
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
19727000
CY2022Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
92906000
CY2021Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
76097000
CY2022 us-gaap Revenues
Revenues
38212000
CY2021 us-gaap Revenues
Revenues
54506000
CY2022 bdsx Direct Costs And Expenses
DirectCostsAndExpenses
14154000
CY2021 bdsx Direct Costs And Expenses
DirectCostsAndExpenses
30518000
CY2022 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
13102000
CY2021 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
12789000
CY2022 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
61462000
CY2021 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
50517000
CY2021 bdsx Change In Fair Value Of Contingent Consideration Excluding Accretion Expense
ChangeInFairValueOfContingentConsiderationExcludingAccretionExpense
1622000
CY2022 us-gaap Impairment Of Intangible Assets Finitelived
ImpairmentOfIntangibleAssetsFinitelived
81000
CY2022 us-gaap Operating Expenses
OperatingExpenses
88799000
CY2021 us-gaap Operating Expenses
OperatingExpenses
95446000
CY2022 us-gaap Operating Income Loss
OperatingIncomeLoss
-50587000
CY2021 us-gaap Operating Income Loss
OperatingIncomeLoss
-40940000
CY2022 us-gaap Interest Expense
InterestExpense
8072000
CY2021 us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
2298000
CY2021 us-gaap Interest Expense
InterestExpense
4508000
CY2022 us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
-6981000
CY2022 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
-84000
CY2022 us-gaap Other Nonoperating Income
OtherNonoperatingIncome
109000
CY2021 us-gaap Other Nonoperating Income
OtherNonoperatingIncome
9000
CY2022 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-14860000
CY2021 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-2219000
CY2022 us-gaap Net Income Loss
NetIncomeLoss
-65447000
CY2021 us-gaap Net Income Loss
NetIncomeLoss
-43159000
CY2022 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.55
CY2022 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.55
CY2021 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.58
CY2021 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.58
CY2022 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
42103000
CY2022 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
42103000
CY2021 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
27365000
CY2021 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
27365000
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
41166000
CY2021 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
15679000
CY2021 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
328000
CY2021 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
769000
CY2021 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
4944000
CY2021 us-gaap Net Income Loss
NetIncomeLoss
-43159000
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
19727000
CY2022 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
56235000
CY2022 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
355000
CY2022 bdsx Stock Issued During Period Values For Deferred Offering Costs
StockIssuedDuringPeriodValuesForDeferredOfferingCosts
600000
CY2022 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
269000
CY2022 us-gaap Adjustments To Additional Paid In Capital Warrant Issued
AdjustmentsToAdditionalPaidInCapitalWarrantIssued
2906000
CY2022 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
5961000
CY2022 us-gaap Net Income Loss
NetIncomeLoss
-65447000
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
20606000
CY2022 us-gaap Profit Loss
ProfitLoss
-65447000
CY2021 us-gaap Profit Loss
ProfitLoss
-43159000
CY2022 us-gaap Depreciation And Amortization
DepreciationAndAmortization
3597000
CY2021 us-gaap Depreciation And Amortization
DepreciationAndAmortization
3178000
CY2022 us-gaap Operating Lease Right Of Use Asset Amortization Expense
OperatingLeaseRightOfUseAssetAmortizationExpense
2247000
CY2022 us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
-6981000
CY2021 us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
2298000
CY2022 us-gaap Share Based Compensation
ShareBasedCompensation
5961000
CY2021 us-gaap Share Based Compensation
ShareBasedCompensation
4944000
CY2022 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
-84000
CY2021 us-gaap Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1
BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
1622000
CY2022 us-gaap Provision For Doubtful Accounts
ProvisionForDoubtfulAccounts
93000
CY2021 us-gaap Provision For Doubtful Accounts
ProvisionForDoubtfulAccounts
193000
CY2022 bdsx Accrued Interest Amortization Of Debt Issuance Costs And Other
AccruedInterestAmortizationOfDebtIssuanceCostsAndOther
5037000
CY2021 bdsx Accrued Interest Amortization Of Debt Issuance Costs And Other
AccruedInterestAmortizationOfDebtIssuanceCostsAndOther
2706000
CY2022 us-gaap Inventory Write Down
InventoryWriteDown
906000
CY2022 us-gaap Impairment Of Intangible Assets Finitelived
ImpairmentOfIntangibleAssetsFinitelived
81000
CY2022 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
1501000
CY2021 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-11454000
CY2022 us-gaap Increase Decrease In Other Current Assets
IncreaseDecreaseInOtherCurrentAssets
-1113000
CY2021 us-gaap Increase Decrease In Other Current Assets
IncreaseDecreaseInOtherCurrentAssets
-1369000
CY2022 us-gaap Increase Decrease In Other Noncurrent Assets And Liabilities Net
IncreaseDecreaseInOtherNoncurrentAssetsAndLiabilitiesNet
3504000
CY2021 us-gaap Increase Decrease In Other Noncurrent Assets And Liabilities Net
IncreaseDecreaseInOtherNoncurrentAssetsAndLiabilitiesNet
-875000
CY2022 us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
-773000
CY2021 us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
-7425000
CY2022 us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
-1213000
CY2021 us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
-1682000
CY2022 bdsx Tenant Improvement Allowances Received
TenantImprovementAllowancesReceived
2471000
CY2022 us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-937000
CY2022 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-44972000
CY2021 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-28223000
CY2022 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
3298000
CY2021 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
2241000
CY2022 bdsx Payments For Proceeds From Patent Costs And Intangible Asset Acquisition Net
PaymentsForProceedsFromPatentCostsAndIntangibleAssetAcquisitionNet
236000
CY2021 bdsx Payments For Proceeds From Patent Costs And Intangible Asset Acquisition Net
PaymentsForProceedsFromPatentCostsAndIntangibleAssetAcquisitionNet
306000
CY2022 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-3534000
CY2021 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-2547000
CY2022 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
59538000
CY2021 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
16343000
CY2022 bdsx Proceeds From Issuance Of Common Stock Under Employee Stock Purchase Plan
ProceedsFromIssuanceOfCommonStockUnderEmployeeStockPurchasePlan
355000
CY2021 bdsx Proceeds From Issuance Of Common Stock Under Employee Stock Purchase Plan
ProceedsFromIssuanceOfCommonStockUnderEmployeeStockPurchasePlan
328000
CY2022 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
269000
CY2021 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
769000
CY2022 us-gaap Payment For Contingent Consideration Liability Financing Activities
PaymentForContingentConsiderationLiabilityFinancingActivities
10822000
CY2022 bdsx Proceeds From Issuance Of Term Loan And Notes Payable
ProceedsFromIssuanceOfTermLoanAndNotesPayable
45102000
CY2021 bdsx Proceeds From Issuance Of Term Loan And Notes Payable
ProceedsFromIssuanceOfTermLoanAndNotesPayable
30078000
CY2022 us-gaap Repayments Of Long Term Debt
RepaymentsOfLongTermDebt
28604000
CY2021 us-gaap Repayments Of Long Term Debt
RepaymentsOfLongTermDebt
45428000
CY2022 us-gaap Payments Of Debt Issuance Costs
PaymentsOfDebtIssuanceCosts
3725000
CY2021 us-gaap Payments Of Debt Issuance Costs
PaymentsOfDebtIssuanceCosts
164000
CY2022 bdsx Payment Of Deferred Offering Costs
PaymentOfDeferredOfferingCosts
129000
CY2022 us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
3069000
CY2021 us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
664000
CY2022 us-gaap Proceeds From Payments For Other Financing Activities
ProceedsFromPaymentsForOtherFinancingActivities
-33000
CY2022 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
58882000
CY2021 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
1262000
CY2022 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
10376000
CY2021 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-29508000
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
32798000
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
62306000
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
43174000
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
32798000
CY2022 bdsx Common Stock Issued For Deferred Offering Costs
CommonStockIssuedForDeferredOfferingCosts
600000
CY2022 bdsx Deferred Offering Costs Amortized Against Additional Paid In Capital
DeferredOfferingCostsAmortizedAgainstAdditionalPaidInCapital
75000
CY2022 bdsx Issuance Of Perceptive Warrants
IssuanceOfPerceptiveWarrants
3051000
CY2022 bdsx Debt Issuance Costs Included In Accounts Payable And Other Accrued Liabilities
DebtIssuanceCostsIncludedInAccountsPayableAndOtherAccruedLiabilities
631000
CY2021 bdsx Debt Issuance Costs Included In Accounts Payable And Other Accrued Liabilities
DebtIssuanceCostsIncludedInAccountsPayableAndOtherAccruedLiabilities
15000
CY2022 bdsx Equity Financing Costs Included In Accounts Payable And Other Accrued Liabilities
EquityFinancingCostsIncludedInAccountsPayableAndOtherAccruedLiabilities
160000
CY2022 bdsx Operating Lease Right Of Use Assets Obtained In Exchange For Lease Liabilities At Adoption Of Asc842
OperatingLeaseRightOfUseAssetsObtainedInExchangeForLeaseLiabilitiesAtAdoptionOfAsc842
1269000
CY2022 us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
3936000
CY2022 us-gaap Right Of Use Asset Obtained In Exchange For Finance Lease Liability
RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability
123000
CY2022 us-gaap Interest Paid Net
InterestPaidNet
1009000
CY2021 us-gaap Interest Paid Net
InterestPaidNet
1676000
CY2022 bdsx Number Of Cancer Test
NumberOfCancerTest
5
CY2022 bdsx Number Of Commercial Blood Based Test
NumberOfCommercialBloodBasedTest
2
CY2022 bdsx Number Of Sars Co V2 Test
NumberOfSARSCoV2Test
3
CY2022Q4 bdsx Gross Proceeds From Financing Transactions
GrossProceedsFromFinancingTransactions
70700000
CY2022Q4 bdsx Net Proceed From Financing Transactionsss
NetProceedFromFinancingTransactionsss
65700000
CY2022Q4 us-gaap Repayments Of Long Term Debt
RepaymentsOfLongTermDebt
23900000
CY2022 us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Concentrations of Credit Risk and Other Uncertainties</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Substantially all of the Company’s cash and cash equivalents are deposited with two major financial institutions in the United States. The Company continually monitors its positions with, and the credit quality of, the financial institution with which it holds cash. Periodically throughout the year, the Company has maintained balances in various operating accounts in excess of federally insured limits. The Company has not experienced any losses on its deposits of cash and cash equivalents.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Several of the components for certain of the Company's sample collection kits, test reagents, and test systems are obtained from single-source suppliers. If these single-source suppliers fail to satisfy the Company's requirements on a timely basis, the Company could suffer delays in being able to deliver its diagnostic solutions, a possible loss of revenue, or incur higher costs, any of which could adversely affect its operating results.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">For a discussion of credit risk concentration of accounts receivable as of December 31, 2022 and 2021, see Note 11 – </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Revenue and Accounts Receivable Credit Concentration</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">.</span></p>
CY2022Q4 us-gaap Restricted Cash
RestrictedCash
100000
CY2021Q4 us-gaap Restricted Cash
RestrictedCash
100000
CY2022Q4 us-gaap Inventory Valuation Reserves
InventoryValuationReserves
100000
CY2021Q4 us-gaap Inventory Valuation Reserves
InventoryValuationReserves
0
CY2022 us-gaap Inventory Write Down
InventoryWriteDown
900000
CY2021 us-gaap Inventory Write Down
InventoryWriteDown
0
CY2022 us-gaap Impairment Of Long Lived Assets Held For Use
ImpairmentOfLongLivedAssetsHeldForUse
0
CY2021 us-gaap Impairment Of Long Lived Assets Held For Use
ImpairmentOfLongLivedAssetsHeldForUse
0
CY2021 us-gaap Impairment Of Intangible Assets Excluding Goodwill
ImpairmentOfIntangibleAssetsExcludingGoodwill
0
CY2022 us-gaap Goodwill Impairment Loss
GoodwillImpairmentLoss
0
CY2022 us-gaap Income Tax Examination Likelihood Of Unfavorable Settlement
IncomeTaxExaminationLikelihoodOfUnfavorableSettlement
For tax positions meeting the more likely than not threshold, the amount recognized in the financial statements is the largest benefit that has a greater than 50 percent likelihood of being realized upon ultimate settlement with the relevant tax authority.
CY2022Q1 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
1300000
CY2022Q1 bdsx Offsetting Deferred Rent
OffsettingDeferredRent
100000
CY2022Q1 us-gaap Operating Lease Liability
OperatingLeaseLiability
1300000
CY2022 us-gaap Lessee Operating Lease Description
LesseeOperatingLeaseDescription
For lease classification determination, Management continues to use (i) 75% or greater to determine whether the lease term is a major part of the remaining economic life of the underlying asset and (ii) 90% or greater to determine whether the present value of the sum of lease payments is substantially all of the fair value of the underlying asset.
CY2022Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
12866000
CY2021Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
10928000
CY2022Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
7018000
CY2021Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
6749000
CY2022Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
5848000
CY2021Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
4179000
CY2022Q4 us-gaap Intangible Assets Gross Excluding Goodwill
IntangibleAssetsGrossExcludingGoodwill
18894000
CY2022Q4 bdsx Intangible Assets Accumulated Amortization Excluding Goodwill
IntangibleAssetsAccumulatedAmortizationExcludingGoodwill
9097000
CY2022Q4 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
9797000
CY2021Q4 us-gaap Intangible Assets Gross Excluding Goodwill
IntangibleAssetsGrossExcludingGoodwill
18755000
CY2021Q4 bdsx Intangible Assets Accumulated Amortization Excluding Goodwill
IntangibleAssetsAccumulatedAmortizationExcludingGoodwill
7138000
CY2021Q4 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
11617000
CY2021Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
7665000
CY2021Q4 bdsx Accrued Clinical Trial Expense Current
AccruedClinicalTrialExpenseCurrent
870000
CY2022Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
2315000
CY2021Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
2766000
CY2022Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
8218000
CY2022 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
1975000
CY2021 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
1950000
CY2022Q4 us-gaap Finite Lived Intangible Assets Amortization Expense Next Twelve Months
FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths
1972000
CY2022Q4 us-gaap Finite Lived Intangible Assets Amortization Expense Year Two
FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo
1963000
CY2022Q4 us-gaap Finite Lived Intangible Assets Amortization Expense Year Three
FiniteLivedIntangibleAssetsAmortizationExpenseYearThree
1957000
CY2022Q4 us-gaap Finite Lived Intangible Assets Amortization Expense Year Four
FiniteLivedIntangibleAssetsAmortizationExpenseYearFour
1943000
CY2022Q4 us-gaap Finite Lived Intangible Assets Amortization Expense Year Five
FiniteLivedIntangibleAssetsAmortizationExpenseYearFive
992000
CY2022Q4 bdsx Finite Lived Intangible Assets Amortization Expense Year Six And Thereafter
FiniteLivedIntangibleAssetsAmortizationExpenseYearSixAndThereafter
856000
CY2022Q4 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
9683000
CY2022Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
4671000
CY2021Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
4029000
CY2022Q4 bdsx Accrued Clinical Trial Expense Current
AccruedClinicalTrialExpenseCurrent
1232000
CY2022Q4 us-gaap Debt Instrument Unamortized Discount Premium And Debt Issuance Costs Net
DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet
5074000
CY2021Q4 us-gaap Debt Instrument Unamortized Discount Premium And Debt Issuance Costs Net
DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet
63000
CY2022Q4 us-gaap Notes Payable
NotesPayable
25053000
CY2021Q4 us-gaap Notes Payable
NotesPayable
10012000
CY2022Q4 us-gaap Notes Payable Current
NotesPayableCurrent
49000
CY2021Q4 us-gaap Notes Payable Current
NotesPayableCurrent
19000
CY2022Q4 us-gaap Long Term Notes Payable
LongTermNotesPayable
25004000
CY2021Q4 us-gaap Long Term Notes Payable
LongTermNotesPayable
9993000
CY2022 bdsx Description Of Securities Purchase Agreement
DescriptionOfSecuritiesPurchaseAgreement
(i) purchased a secured promissory note (Promissory Note One) in the aggregate principal amount totaling $16.0 million in exchange for $15.0 million less certain expenses and (ii) agreed to purchase another secured promissory note at the Company’s election (Promissory Note Two and, together with Promissory Note One, the Promissory Notes), subject to certain conditions precedent in aggregate principal amount totaling $10.3 million in exchange for $10.0 million in cash proceeds.
CY2022Q2 us-gaap Derivative Fixed Interest Rate
DerivativeFixedInterestRate
0.06
CY2022Q2 us-gaap Derivative Term Of Contract
DerivativeTermOfContract
P24M
CY2022Q2 bdsx Promissory Notes Early Prepayment Premium Percentage
PromissoryNotesEarlyPrepaymentPremiumPercentage
0.10
CY2022 bdsx Accrued Interest Amortization Of Original Issue Discount And Debt Issuance Costs
AccruedInterestAmortizationOfOriginalIssueDiscountAndDebtIssuanceCosts
1800000
CY2022 us-gaap Debt Instrument Description
DebtInstrumentDescription
The 2021 Term Loan provided for an “interest-only” period from the Effective Date through February 28, 2023, with interest due and payable monthly on the first calendar day of each month. However, the Company achieved a revenue milestone of at least $65 million on a trailing twelve-month basis during the three months ended March 31, 2021 which automatically extended the interest-only period through February 28, 2024. Beginning on the first calendar day of the month following the end of the interest-only period, the 2021 Term Loan was payable in (i) consecutive equal installments of principal through March 1, 2026, plus (ii) monthly payments of accrued interest. The principal amount outstanding under the 2021 Term Loan accrued interest at a floating per annum rate equal to the greater of (i) 2.00% above the prime rate, or (ii) 5.25%, which interest, in each case, was payable monthly. Changes to the interest rate applicable to the 2021 Term Loan based on changes to the prime rate were effective on the effective date of any change to the prime rate.
CY2022Q4 us-gaap Long Term Debt Maturities Repayments Of Principal In Next Twelve Months
LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths
49000
CY2022Q4 us-gaap Long Term Debt Maturities Repayments Of Principal In Year Two
LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo
50000
CY2022Q4 us-gaap Long Term Debt Maturities Repayments Of Principal In Year Three
LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree
21000
CY2022Q4 us-gaap Long Term Debt Maturities Repayments Of Principal In Year Four
LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour
7000
CY2022Q4 us-gaap Long Term Debt Maturities Repayments Of Principal In Year Five
LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive
30000000
CY2022 bdsx Primary Sources Of Revenue Description
PrimarySourcesOfRevenueDescription
We derive our revenue from two primary sources: (i) providing diagnostic testing in the clinical setting (Diagnostic tests); and (ii) providing biopharmaceutical companies with services that include diagnostic research, clinical research, clinical trial testing, development and testing services generally provided outside the clinical setting and governed by individual contracts with third parties as well as development and commercialization of companion diagnostics (Services).
CY2022Q4 us-gaap Long Term Debt
LongTermDebt
30127000
CY2022 us-gaap Operating Lease Expense
OperatingLeaseExpense
2600000
CY2021 us-gaap Operating Lease Expense
OperatingLeaseExpense
1200000
CY2022Q4 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P9Y
CY2022Q4 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.1140
CY2022Q4 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
2289000
CY2022Q4 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
2619000
CY2022Q4 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
3710000
CY2022Q4 us-gaap Lessee Operating Lease Liability Payments Due Year Four
LesseeOperatingLeaseLiabilityPaymentsDueYearFour
3978000
CY2022Q4 us-gaap Lessee Operating Lease Liability Payments Due Year Five
LesseeOperatingLeaseLiabilityPaymentsDueYearFive
4063000
CY2022Q4 bdsx Lessee Operating Lease Liability To Be Paid Year Six And Thereafter
LesseeOperatingLeaseLiabilityToBePaidYearSixAndThereafter
32263000
CY2022Q4 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
48922000
CY2022Q4 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
23802000
CY2022Q4 bdsx Lessee Operating Lease Liability Amount Representing Tenant Improvement Allowances
LesseeOperatingLeaseLiabilityAmountRepresentingTenantImprovementAllowances
18323000
CY2022Q4 us-gaap Operating Lease Liability
OperatingLeaseLiability
6797000
CY2022Q4 bdsx Tenant Improvement Allowances Expected To Be Received
TenantImprovementAllowancesExpectedToBeReceived
18300000
CY2021Q4 us-gaap Operating Leases Future Minimum Payments Due Current
OperatingLeasesFutureMinimumPaymentsDueCurrent
775000
CY2021Q4 us-gaap Operating Leases Future Minimum Payments Due In Two Years
OperatingLeasesFutureMinimumPaymentsDueInTwoYears
149000
CY2021Q4 us-gaap Operating Leases Future Minimum Payments Due In Three Years
OperatingLeasesFutureMinimumPaymentsDueInThreeYears
9000
CY2021Q4 us-gaap Operating Leases Future Minimum Payments Due In Four Years
OperatingLeasesFutureMinimumPaymentsDueInFourYears
3000
CY2021Q4 us-gaap Operating Leases Future Minimum Payments Due In Five Years
OperatingLeasesFutureMinimumPaymentsDueInFiveYears
1000
CY2021Q4 us-gaap Operating Leases Future Minimum Payments Due
OperatingLeasesFutureMinimumPaymentsDue
937000
CY2022Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
200000000
CY2022Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2022 us-gaap Common Stock Voting Rights
CommonStockVotingRights
The holder of each share of common stock is entitled to one vote per share.
CY2022 us-gaap Dividends Common Stock
DividendsCommonStock
0
CY2022Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000
CY2022Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2022Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2022Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2021Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2021Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2022Q4 us-gaap Warrants And Rights Outstanding Maturity Date
WarrantsAndRightsOutstandingMaturityDate
2028-02-23
CY2022 us-gaap Revenues
Revenues
38212000
CY2021 us-gaap Revenues
Revenues
54506000
CY2021Q4 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
1900000
CY2021 us-gaap Contract With Customer Liability Revenue Recognized
ContractWithCustomerLiabilityRevenueRecognized
1200000
CY2022Q4 us-gaap Contract With Customer Liability Noncurrent
ContractWithCustomerLiabilityNoncurrent
400000
CY2022Q4 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
1000000.0
CY2022 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
5961000
CY2021 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
4944000
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
2878000
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
8.08
CY2021 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P7Y8M12D
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
6288000
CY2022 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
380000
CY2022 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
2.92
CY2022 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod
333000
CY2022 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice
8.23
CY2022 us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
384000
CY2022 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
0.70
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
2541000
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
8.40
CY2022 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P7Y4M24D
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
1489000
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
1525000
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
7.28
CY2022 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P6Y9M18D
CY2022Q4 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
1067000
CY2022 us-gaap Dividends Common Stock
DividendsCommonStock
0
CY2021 us-gaap Dividends Common Stock
DividendsCommonStock
0
CY2021 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
27365000
CY2022 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.55
CY2022 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P5Y7M24D
CY2021 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P6Y3D
CY2022 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.726
CY2021 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.685
CY2022 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.0132
CY2021 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.0079
CY2021Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
2520108
CY2021Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
2520108
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
2520108
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
2520108
CY2020 us-gaap Net Income Loss
NetIncomeLoss
-65447000
CY2021 us-gaap Net Income Loss
NetIncomeLoss
-43159000
CY2022 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
42103000
CY2022 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
42103000
CY2021 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
27365000
CY2021Q4 us-gaap Deferred Tax Assets Property Plant And Equipment
DeferredTaxAssetsPropertyPlantAndEquipment
215000
CY2022 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.55
CY2021 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.58
CY2021 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.58
CY2022 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
9461000
CY2021 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
3535000
CY2022 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
CY2022 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.21
CY2021 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.21
CY2022 us-gaap Effective Income Tax Rate Reconciliation State And Local Income Taxes
EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
0.05
CY2021 us-gaap Effective Income Tax Rate Reconciliation State And Local Income Taxes
EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
0.05
CY2022 us-gaap Effective Income Tax Rate Reconciliation Tax Credits Research
EffectiveIncomeTaxRateReconciliationTaxCreditsResearch
0.01
CY2021 us-gaap Effective Income Tax Rate Reconciliation Tax Credits Research
EffectiveIncomeTaxRateReconciliationTaxCreditsResearch
0.01
CY2022 bdsx Effective Income Tax Rate Reconciliation Permanent Items
EffectiveIncomeTaxRateReconciliationPermanentItems
0.04
CY2021 bdsx Effective Income Tax Rate Reconciliation Permanent Items
EffectiveIncomeTaxRateReconciliationPermanentItems
0.01
CY2022 us-gaap Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
-0.23
CY2021 us-gaap Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
-0.26
CY2022Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
70822000
CY2021Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
61874000
CY2022Q4 us-gaap Deferred Tax Assets Tax Credit Carryforwards Research
DeferredTaxAssetsTaxCreditCarryforwardsResearch
3807000
CY2021Q4 us-gaap Deferred Tax Assets Tax Credit Carryforwards Research
DeferredTaxAssetsTaxCreditCarryforwardsResearch
3372000
CY2022Q4 us-gaap Deferred Tax Asset Interest Carryforward
DeferredTaxAssetInterestCarryforward
3036000
CY2021Q4 us-gaap Deferred Tax Asset Interest Carryforward
DeferredTaxAssetInterestCarryforward
554000
CY2022Q4 us-gaap Deferred Tax Assets Property Plant And Equipment
DeferredTaxAssetsPropertyPlantAndEquipment
234000
CY2022Q4 bdsx Deferred Tax Assets Capitalized Research Costs
DeferredTaxAssetsCapitalizedResearchCosts
2874000
CY2022Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
1619000
CY2021Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
1977000
CY2022Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Reserves And Accruals
DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals
1932000
CY2021Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Reserves And Accruals
DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals
1618000
CY2022Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
84324000
CY2021Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
69610000
CY2022Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
82552000
CY2021Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
67457000
CY2022Q4 us-gaap Deferred Tax Assets Net
DeferredTaxAssetsNet
1772000
CY2021Q4 us-gaap Deferred Tax Assets Net
DeferredTaxAssetsNet
2153000
CY2022Q4 us-gaap Deferred Tax Liabilities Goodwill And Intangible Assets Intangible Assets
DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets
1772000
CY2021Q4 us-gaap Deferred Tax Liabilities Goodwill And Intangible Assets Intangible Assets
DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets
2153000
CY2022Q4 us-gaap Deferred Income Tax Liabilities
DeferredIncomeTaxLiabilities
1772000
CY2021Q4 us-gaap Deferred Income Tax Liabilities
DeferredIncomeTaxLiabilities
2153000
CY2022Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards Subject To Expiration
DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration
299900000
CY2022Q4 bdsx Deferred Tax Assets Research And Experimentation Tax Carryforwards Subject To Expiration
DeferredTaxAssetsResearchAndExperimentationTaxCarryforwardsSubjectToExpiration
4800000
CY2022 us-gaap Tax Credit Carryforward Description
TaxCreditCarryforwardDescription
expire beginning in 2026
CY2022 us-gaap Valuation Allowance Deferred Tax Asset Explanation Of Change
ValuationAllowanceDeferredTaxAssetExplanationOfChange
Company does not believe it is more likely than not that it will realize the benefits of net deferred tax assets and, accordingly, has established a valuation allowance equal to 100% of net deferred tax assets.
CY2022 bdsx Percentage Of Valuation Allowance Equal To Net Deferred Tax Assets
PercentageOfValuationAllowanceEqualToNetDeferredTaxAssets
1
CY2022 us-gaap Valuation Allowance Deferred Tax Asset Change In Amount
ValuationAllowanceDeferredTaxAssetChangeInAmount
15100000
CY2021 us-gaap Valuation Allowance Deferred Tax Asset Change In Amount
ValuationAllowanceDeferredTaxAssetChangeInAmount
11400000
CY2022Q4 us-gaap Unrecognized Tax Benefits Interest On Income Taxes Accrued
UnrecognizedTaxBenefitsInterestOnIncomeTaxesAccrued
0
CY2021Q4 us-gaap Unrecognized Tax Benefits Interest On Income Taxes Accrued
UnrecognizedTaxBenefitsInterestOnIncomeTaxesAccrued
0
CY2021Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
843000
CY2020Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
715000
CY2022 us-gaap Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions
UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions
109000
CY2021 us-gaap Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions
UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions
128000
CY2022Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
952000
CY2021Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
843000
CY2022 us-gaap Income Tax Examination Description
IncomeTaxExaminationDescription
federal and state returns for all years will remain open to examination by federal and state tax authorities for three and four years, respectively, from the date of utilization of any net operating loss carryforwards.

Files In Submission

Name View Source Status
0000950170-23-006092-index-headers.html Edgar Link pending
0000950170-23-006092-index.html Edgar Link pending
0000950170-23-006092.txt Edgar Link pending
0000950170-23-006092-xbrl.zip Edgar Link pending
bdsx-20221231.htm Edgar Link pending
bdsx-20221231.xsd Edgar Link pending
bdsx-ex10_83.htm Edgar Link pending
bdsx-ex23_1.htm Edgar Link pending
bdsx-ex31_1.htm Edgar Link pending
bdsx-ex31_2.htm Edgar Link pending
bdsx-ex32_1.htm Edgar Link pending
bdsx-ex32_2.htm Edgar Link pending
Financial_Report.xlsx Edgar Link pending
img34454307_0.jpg Edgar Link pending
img34454307_1.jpg Edgar Link pending
img34454307_2.jpg Edgar Link pending
img34454307_3.jpg Edgar Link pending
img34454307_4.jpg Edgar Link pending
bdsx-20221231_cal.xml Edgar Link unprocessable
bdsx-20221231_def.xml Edgar Link unprocessable
bdsx-20221231_lab.xml Edgar Link unprocessable
FilingSummary.xml Edgar Link unprocessable
bdsx-20221231_pre.xml Edgar Link unprocessable
bdsx-20221231_htm.xml Edgar Link completed
img34454307_5.jpg Edgar Link pending
img34454307_6.jpg Edgar Link pending
img34454307_7.jpg Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R58.htm Edgar Link pending
R59.htm Edgar Link pending
R6.htm Edgar Link pending
R60.htm Edgar Link pending
R61.htm Edgar Link pending
R62.htm Edgar Link pending
R63.htm Edgar Link pending
R64.htm Edgar Link pending
R65.htm Edgar Link pending
R66.htm Edgar Link pending
R67.htm Edgar Link pending
R68.htm Edgar Link pending
R69.htm Edgar Link pending
R7.htm Edgar Link pending
R70.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending